螺丝刀
发表于 2025-3-21 16:50:19
书目名称Novel Therapeutics for Rare Lymphomas影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0668467<br><br> <br><br>书目名称Novel Therapeutics for Rare Lymphomas读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0668467<br><br> <br><br>
愤怒事实
发表于 2025-3-21 23:17:35
http://reply.papertrans.cn/67/6685/668467/668467_2.png
沙发
发表于 2025-3-22 00:27:03
Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas,e Ki-1 antibody binding to Reed-Sternberg cells in Hodgkin lymphoma (Stein et al., Blood 66(4):848–858, 1985). Since it has high expression within Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), variable expression in other non-Hodgkin lymphoma subgroups, and limited expression in n
一起平行
发表于 2025-3-22 05:26:29
http://reply.papertrans.cn/67/6685/668467/668467_4.png
叙述
发表于 2025-3-22 12:40:50
http://reply.papertrans.cn/67/6685/668467/668467_5.png
极少
发表于 2025-3-22 15:01:10
http://reply.papertrans.cn/67/6685/668467/668467_6.png
敲竹杠
发表于 2025-3-22 19:32:55
http://reply.papertrans.cn/67/6685/668467/668467_7.png
烤架
发表于 2025-3-23 00:40:29
Novel Agents in Primary Central Nervous System Lymphoma,te-based therapies has improved patient outcomes in the first-line setting, the prognosis of relapsed and refractory disease is poor. PCNSL has a unique pathophysiology and gene expression profile, making it more amenable to novel targeted and immunotherapeutic agents. Therapies such as ibrutinib, n
Outmoded
发表于 2025-3-23 05:16:09
http://reply.papertrans.cn/67/6685/668467/668467_9.png
Bouquet
发表于 2025-3-23 09:04:24
Extranodal NK/T-Cell Lymphoma,and is characterized by localized lesions involving the nose, nasopharynx, or oropharynx. Extra-nasal disease is less common and generally more aggressive. The immunophenotype of ENKTCL is unique, with most cases expressing NK-cell markers (CD2+, cytoplasmic CD3+, and CD56+). Treatment options for l